Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (82 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 102 | 29% |
| 2020 | 1 | 89 | 32% |
| 2021 | 1 | 110 | 37% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arkansas; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 39 | 2,201−3.4%/yr | −3.4%/yr | 6.20.9× | 36% | 2,190 in 2030−0.1%/yr |
| Tumor & fibroid embolization |
Tumor ablation in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Florida
| ≈ 120 |
| – |
| 2026 est. | ≈ 120 | – |
| 2022 | 0 | 51 | 40% |
| 2023 | 0 | 89 | 46% |
| 2024 | 2 | 104 | 49% |
| 2025 from claims | – | 118 96–139 | 50% |
| 2026 forecast | – | 123 98–156 | 51% |
| 2027 forecast | – | 129 97–172 | 51% |
| 2028 forecast | – | 135 97–188 | 52% |
| 2029 forecast | – | 141 98–205 | 53% |
| 2030 forecast | – | 147 99–222 | 53% |
In 2025, 57% hospital outpatient, 43% surgery center.
| −0.3%/yr |
| 0.4 |
| 0% |
| 1,000 in 2030+4.6%/yr |
| North Carolina | 3 | 333−1.7%/yr | −1.7%/yr | 0.3 | 0% | 320 in 2030−0.6%/yr |
| Georgia | 2 | 333+1.5%/yr | +1.5%/yr | 0.4 | 0% | 260 in 2030−3.9%/yr |
| Virginia | 1 | 278+2.6%/yr | +2.6%/yr | 0.3 | 0% | 470 in 2030+9%/yr |
| Maryland | 5 | 276+6.9%/yr | +6.9%/yr | 0.3 | 0% | 670 in 2030+16%/yr |
| South Carolina | 2 | 219+0.1%/yr | +0.1%/yr | 0.3 | 0% | 270 in 2030+3.2%/yr |
| Tennessee | 3 | 209+1%/yr | +1%/yr | 0.3 | 0% | 280 in 2030+4.9%/yr |
| Alabama | 0 | 111+2.7%/yr | +2.7%/yr | 0.3 | 0% | 150 in 2030+4.8%/yr |
| Louisiana | 0 | 111+4.1%/yr | +4.1%/yr | 0.3 | 0% | 290 in 2030+17%/yr |
| 3 |
| 163−1.5%/yr |
| −1.5%/yr |
| 0.40.8× |
| 73% |
| 730 in 2030+29%/yr |
Angiodynamics leads with 44% of company spending on these surgeons in 2025, +42 pts on 2024.
In 2025, 13 companies reported engagement with Arkansas’s surgeons worth $107K in consulting, speaking, meals and travel tied to these products, about $54K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.